To study the impact of alcaftadine in patients treated with other opthalmic ocular agents (or specific topical opthalmic treatment) in an allergy subspecialist outpatient setting.
To assess the impact of ocular allergy treatment on patients using an ophthalmic agent (or no treatment) versus alcaftadine(Lastacaft™)
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
50
Alcaftadine 0.25% one dorp each eye daily for 1-2 weeks.
STARx Research Center
Edison, New Jersey, United States
RECRUITINGSTARx
Springfield, New Jersey, United States
RECRUITINGQuality of Life- Eye Allergy Patient Impact Questionnaire
Time frame: 4 months
Ocular Surface Disease Index Pollen Count correlation of symptoms
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.